CE2025-01-16T15:54:28
The drug is the first biologic in over 15 years to have disclosed two-year Phase III efficacy data in Crohn's disease at the time of approval.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-07-13T07:00:00
Sponsored by Thermo Fisher Scientific
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-05-22T14:48:00
Sponsored by CPhI
2026-09-16T15:00:00
Sponsored by BioDuro
Site powered by Webvision Cloud